secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001297184-25-000054
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar enters $2.8M R&D agreement with related-party Hanxin for AMP-107 cell banks
--------------------------------------------------------------------------------

- Agreement with Nanjing Hanxin to develop Recombinant Peptide Research Cell Banks (RCBs) for product candidate AMP-107.
- Total cost not to exceed ~$2.8M; initial payment ~$0.3M; payments in Chinese yuan.
- Hanxin majority-owned by CEO Jack Zhang, Chairman Mary Luo, and family; approved by independent audit committee.
- Term of three years; all title to RCBs and related IP will belong to Amphastar.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000054/0001297184-25-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000054/amph-20250915x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-25-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer